- Home
- AIRS vs AMRN Comparison
AIRS vs AMRN Comparison
Compare AIRS & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- AMRN
- Stock Information
- Founded
- AIRS 2012
- AMRN 1989
- Country
- AIRS United States
- AMRN Ireland
- Employees
- AIRS N/A
- AMRN N/A
- Industry
- AIRS Medical/Nursing Services
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- AMRN Health Care
- Exchange
- AIRS Nasdaq
- AMRN Nasdaq
- Market Cap
- AIRS 400.5M
- AMRN 189.2M
- IPO Year
- AIRS 2021
- AMRN 1993
- Fundamental
- Price
- AIRS $5.40
- AMRN $0.44
- Analyst Decision
- AIRS Hold
- AMRN Buy
- Analyst Count
- AIRS 2
- AMRN 1
- Target Price
- AIRS $5.00
- AMRN N/A
- AVG Volume (30 Days)
- AIRS 233.2K
- AMRN 1.7M
- Earning Date
- AIRS 02-25-2025
- AMRN 02-27-2025
- Dividend Yield
- AIRS N/A
- AMRN N/A
- EPS Growth
- AIRS N/A
- AMRN N/A
- EPS
- AIRS N/A
- AMRN N/A
- Revenue
- AIRS $188,780,000.00
- AMRN $241,021,000.00
- Revenue This Year
- AIRS N/A
- AMRN N/A
- Revenue Next Year
- AIRS $10.31
- AMRN N/A
- P/E Ratio
- AIRS N/A
- AMRN N/A
- Revenue Growth
- AIRS N/A
- AMRN N/A
- 52 Week Low
- AIRS $2.92
- AMRN $0.43
- 52 Week High
- AIRS $9.20
- AMRN $1.37
- Technical
- Relative Strength Index (RSI)
- AIRS 41.39
- AMRN 38.11
- Support Level
- AIRS $5.18
- AMRN $0.43
- Resistance Level
- AIRS $5.68
- AMRN $0.49
- Average True Range (ATR)
- AIRS 0.43
- AMRN 0.03
- MACD
- AIRS -0.06
- AMRN 0.00
- Stochastic Oscillator
- AIRS 18.56
- AMRN 10.56
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.